Literature DB >> 9036354

[Cost-effectiveness of influenza vaccination The Netherlands].

A Reinders1, M J Postma, T M Govaert, M J Sprenger.   

Abstract

OBJECTIVE: To determine the cost-effectiveness of influenza vaccination of all people aged 65 or over in the Netherlands.
DESIGN: Model calculations.
SETTING: National Institute of Public Health and Environment, Bilthoven, the Netherlands.
METHOD: The cost-effectiveness of vaccination strategies was calculated using a mathematical model, with which the epidemiological effects in terms of morbidity and mortality as well as the direct costs of care of an influenza epidemic can be determined. The cost-effectiveness of non-intervention, of the current vaccination scenario for risk groups, and of an alternative scenario involving vaccination of all persons aged 65 or over and of all younger persons in risk groups, was calculated.
RESULTS: Influenza-related care (the number of GP contacts and hospital days) and related costs decreased more with the alternative than with the current risk group scenario. Although the costs of care decreased when more people were vaccinated, the cost of vaccination increased more so that total net costs rose (55 million guilders versus 24 million). In the alternative scenario yearly 1115 life years more were won than with the current practice.
CONCLUSION: Vaccinating all risk groups and all persons aged 65 or more has a favourable cost-effect ratio in comparison with other preventive intervention programmes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9036354

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Influenza vaccination in 29 countries. An update to 1997.

Authors:  F Ambrosch; D S Fedson
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

2.  Economic evaluation of seasonal influenza vaccination in elderly and health workers: A systematic review and meta-analysis.

Authors:  Piyameth Dilokthornsakul; Le My Lan; Ammarin Thakkinstian; Raymond Hutubessy; Philipp Lambach; Nathorn Chaiyakunapruk
Journal:  EClinicalMedicine       Date:  2022-04-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.